BLCO (Bausch + Lomb) — Distributor concentration and global reach: what investors need to know

Bausch + Lomb (BLCO) develops, manufactures and sells eye‑health products and monetizes primarily through point‑of‑sale product sales to wholesalers, retailers and eye‑care practices; revenues are recognized at the point customers obtain control (generally on shipment or receipt). Two large healthcare distributors — McKesson and Cardinal Health — each accounted for 10% of 2024 revenues, creating a meaningful commercial concentration in the wholesale channel against a global sales footprint. For investors and operators assessing customer risk and commercial leverage, the interplay of spot sales, large counterparties and regulatory exposure in key regions defines both downside and scaling opportunity.
If you want a consolidated view of commercial counterparties and implications for risk, see our customer relationship analytics at https://nullexposure.com/.

Market‑facing thesis in one line

• BLCO’s revenue model is driven by high‑volume, spot product sales into major wholesale and retail channels; the business is dependent on a small set of large enterprise distributors for material portions of revenue, while maintaining a global market presence that exposes it to regional regulatory shifts.

Where the concentration shows up and why it matters

• According to BLCO’s FY2024 Form 10‑K (filed for the year ended December 31, 2024), McKesson Corporation and Cardinal Health each represented 10% of total revenues in 2024, and BLCO’s total reported revenue for 2024 was $4,791 million. Those line items make these relationships financially material and worthy of focused diligence.
• The company also discloses that its two largest U.S. and Canada wholesaler customers represented approximately 17% of net trade receivables as of December 31, 2024 — a sign that working capital and collections are meaningfully tied to wholesale partners (FY2024 Form 10‑K).

If you want ongoing tracking of BLCO’s counterparty exposures and receivables concentration, visit https://nullexposure.com/ for real‑time signals.

Who the relationships are (direct from company filings)

• McKesson Corporation — McKesson accounted for 10% of BLCO’s total revenues in 2024, making it one of the company’s largest wholesale customers and a key distribution partner for North American sales (FY2024 Form 10‑K).
• Cardinal Health, Inc. — Cardinal Health also represented 10% of total revenues in 2024, providing parity in top‑customer concentration and reinforcing the company’s dependence on major healthcare distributors (FY2024 Form 10‑K).

What BLCO’s sales dynamics and constraints imply for investors and operators

• Contracting posture: spot sales. BLCO recognizes product revenue at a point in time, typically when the customer obtains control on shipment or receipt; this indicates short-term revenue realization with limited long‑dated contractual revenue guarantees (FY2024 Form 10‑K).
• Customer type: large enterprises. The company states a significant portion of product sales flow to major healthcare distributors and retail chains across North America and internationally, signaling counterparty size and negotiation leverage resting with a few large buyers (FY2024 Form 10‑K).
• Channel role: distributor/reseller network. BLCO sells through wholesalers, retailers and eye‑care professionals; it uses both direct sales forces and independent distributors, which spreads go‑to‑market risk but concentrates financial exposure in large wholesalers (FY2024 Form 10‑K).
• Geography: global, with material NA and EMEA exposure. BLCO sells in roughly 100 countries, reports a large share of revenue in the U.S. and Puerto Rico, and calls out EEA regulatory changes that affect existing and pipeline medical device products — a regional regulatory dependence that can influence market access and product registration timelines (FY2024 Form 10‑K).
• Materiality and spend band: significant. Two customers hit the 10% revenue threshold in 2024; by company accounting they are material to consolidated financials and imply at least $100M+ spend bands per customer on a trailing‑twelve‑month basis given total revenue of roughly $4.8B (FY2024 Form 10‑K).
• Service revenue is not a major offset. Contract manufacturing and contract services are disclosed as not material, which underscores that the core economics are product sales rather than recurring service contracts (FY2024 Form 10‑K).

Practical diligence checklist for investors

• Validate revenue concentration trends: confirm whether McKesson and Cardinal remain at or above the 10% threshold in the latest period and whether any replacement or diversification is underway.
• Assess working capital sensitivity: model the impact of delayed collections or pricing pressure from the two large wholesalers given their ~17% share of net trade receivables.
• Quantify regulatory timing risk in EMEA: inventory which product lines rely on EEA registration for broader market access and the potential timelines and costs to regain or maintain approvals.
• Evaluate channel negotiation dynamics: examine margin compression risk if large distributors demand price concessions or extended payment terms.
• Review customer contractual terms where available: while revenue is mostly spot, investigate any rebate, rebate accruals or variable consideration (the company reported significant rebate accruals in FY2024) that could affect near‑term cash flow.

Key risks and opportunities

• Risk — concentration on two wholesale giants creates negotiation and receivables vulnerability; a shift in ordering patterns or pricing could compress margins or impede cash conversion.
• Risk — EMEA regulatory changes that affect medical device registrations carry product‑access and timing risks for categories that rely on those approvals.
• Opportunity — BLCO’s global footprint and diversified retail channels provide levers to rebalance customer concentration over time through direct retail expansion, geographic growth, and product innovation.
• Opportunity — Improving mix toward higher‑margin or direct channels would reduce dependency on the wholesale corridor and improve predictability of revenue per customer.

Bottom line and investor action

• BLCO’s commercial model is high‑volume, spot sales to a limited set of very large distribution partners, and that concentration is financially material today. Investors should prioritize counterparty exposure, receivables sensitivity, and regional regulatory timelines in any valuation or credit analysis (FY2024 Form 10‑K). For ongoing monitoring of customer relationships and material counterparties, use our curated coverage at https://nullexposure.com/.

If you want tailored analysis or an updated counterparty map for BLCO as filings or customer disclosures evolve, go to https://nullexposure.com/ to request coverage or alerts.